Aspen Puts Up $1B For Pair Of GSK Blood Thinners

Law360, New York (September 30, 2013, 3:36 PM EDT) -- Aspen Pharmacare Holdings Ltd. furthered its expansion push on Monday with an agreement to pay £700 million ($1.1 billion) for a pair of GlaxoSmithKline PLC thrombosis drug brands and a related manufacturing facility, piling onto a growing asset cache that has fueled significant gains.

A firmed-up sale plan comes three months after Aspen first dangled its bid for GSK's Arixtra and Fraxiparine blood-thinning treatments plus the plant, kicking off exclusive negotiations between the companies. GSK holds an 18.6 percent stake in Aspen, South Africa's biggest generic-drug...
To view the full article, register now.